EE635 Direct Comparison of Prophylaxis Cost in Patients With Severe Hemophilia A With and Without Inhibitors With Hemostatic Agents Versus the Use of Emicizumab in Guatemala
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.874
https://www.valueinhealthjournal.com/article/S1098-3015(22)03078-9/fulltext
Title :
EE635 Direct Comparison of Prophylaxis Cost in Patients With Severe Hemophilia A With and Without Inhibitors With Hemostatic Agents Versus the Use of Emicizumab in Guatemala
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03078-9&doi=10.1016/j.jval.2022.09.874
First page :
Section Title :
Open access? :
No
Section Order :
10420